zalypsis

Zalypsis is a semi-synthetic tetrahydroisoquinoline alkaloid structurally related to marine-derived compounds such as jorumycin and ecteinascidins. It acts as a DNA-binding agent that covalently binds to the minor groove of DNA, preferentially at guanine-rich sequences. This interaction leads to inhibition of transcription and cell cycle progression, induction of S-phase arrest, double-stranded DNA breaks (DSBs), and ultimately apoptosis in tumor cells[1][3][6]. Zalypsis has demonstrated potent antitumor activity in preclinical models across various solid tumors and hematological malignancies including multiple myeloma and acute myeloid leukemia[1][3][6][8]. The drug has been evaluated in phase I/II clinical trials for diseases such as lymphoma, solid tumors, Ewing's sarcoma, endometrial cancer, uterine cervical cancer, and multiple myeloma[2][7]. Its development status remains investigational.

Brand names

Zalypsis

Other names

synthetic alkaloid PM00104tetrahydroisoquinoline alkaloid PM00104